• Mithra grants exclusive license to Megalabs for commercialization of its vaginal contraceptive ring in Mexico
  • Strengthening of the commercial presence in Latin and South America thanks to this second contract with Megalabs
  • Myring™ licenses granted to industry leaders in 35 countries, including the world's three largest markets

Liege, Belgium, 14 July 2020 - 7:30 CEST - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces that it has entered into a license and supply agreement (LSA) with Megalabs for the commercialization of its hormonal contraceptive ring Myring™ in Mexico. Based in Uruguay, Megalabs develops a wide range of market-leading pharmaceutical products in twenty Latin American countries

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 14 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 July 2020 05:40:00 UTC